GSK PLC Sponsored ADR $GSK Shares Purchased by Jacobi Capital Management LLC

by · The Cerbat Gem

Jacobi Capital Management LLC boosted its stake in GSK PLC Sponsored ADR (NYSE:GSK – Free Report) by 6.2% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 11,043 shares of the pharmaceutical company’s stock after buying an additional 640 shares during the period. Jacobi Capital Management LLC’s holdings in GSK were worth $428,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the business. Dodge & Cox increased its holdings in shares of GSK by 14.9% during the first quarter. Dodge & Cox now owns 78,651,833 shares of the pharmaceutical company’s stock valued at $3,046,972,000 after purchasing an additional 10,210,921 shares during the period. Primecap Management Co. CA increased its holdings in shares of GSK by 1.8% during the first quarter. Primecap Management Co. CA now owns 25,708,020 shares of the pharmaceutical company’s stock valued at $995,929,000 after purchasing an additional 446,360 shares during the period. Price T Rowe Associates Inc. MD increased its holdings in shares of GSK by 2.1% during the first quarter. Price T Rowe Associates Inc. MD now owns 7,722,314 shares of the pharmaceutical company’s stock valued at $299,163,000 after purchasing an additional 155,392 shares during the period. Royal Bank of Canada increased its holdings in shares of GSK by 5.7% during the first quarter. Royal Bank of Canada now owns 7,581,079 shares of the pharmaceutical company’s stock valued at $293,692,000 after purchasing an additional 411,869 shares during the period. Finally, Equity Investment Corp increased its holdings in shares of GSK by 5.3% during the first quarter. Equity Investment Corp now owns 4,174,189 shares of the pharmaceutical company’s stock valued at $161,708,000 after purchasing an additional 211,608 shares during the period. 15.74% of the stock is owned by institutional investors and hedge funds.

GSK Trading Down 1.6%

Shares of GSK stock opened at $40.81 on Friday. The stock has a 50-day simple moving average of $38.74 and a 200 day simple moving average of $38.46. GSK PLC Sponsored ADR has a fifty-two week low of $31.72 and a fifty-two week high of $43.62. The stock has a market capitalization of $83.12 billion, a P/E ratio of 18.89, a P/E/G ratio of 2.07 and a beta of 0.53. The company has a quick ratio of 0.57, a current ratio of 0.87 and a debt-to-equity ratio of 1.07.

GSK (NYSE:GSK – Get Free Report) last announced its earnings results on Wednesday, July 30th. The pharmaceutical company reported $1.23 earnings per share for the quarter, beating the consensus estimate of $1.12 by $0.11. GSK had a return on equity of 49.22% and a net margin of 10.81%.The business had revenue of $10.64 billion during the quarter, compared to analysts’ expectations of $7.92 billion. During the same quarter last year, the business posted $0.43 earnings per share. The company’s quarterly revenue was up 1.3% on a year-over-year basis. GSK has set its FY 2025 guidance at 4.590-4.590 EPS. On average, sell-side analysts expect that GSK PLC Sponsored ADR will post 4.14 earnings per share for the current fiscal year.

GSK Cuts Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, October 9th. Investors of record on Friday, August 15th will be paid a dividend of $0.4206 per share. The ex-dividend date of this dividend is Friday, August 15th. This represents a $1.68 annualized dividend and a yield of 4.1%. GSK’s dividend payout ratio (DPR) is currently 77.78%.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on GSK shares. Berenberg Bank reissued a “hold” rating on shares of GSK in a report on Tuesday, June 3rd. Wall Street Zen raised GSK from a “buy” rating to a “strong-buy” rating in a report on Friday, September 5th. Six equities research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Reduce” and an average price target of $37.38.

Get Our Latest Analysis on GSK

GSK Profile

(Free Report)

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.

Recommended Stories

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GSK PLC Sponsored ADR (NYSE:GSK – Free Report).